Scientific Authority in Iranian Pharmaceutical Sciences Research Centers: The Results of a Decade Research Evaluation Scientific Authority in Pharmaceutical Research Center
Iranian Journal of Pharmaceutical Sciences,
Vol. 20 No. 2 (2024),
23 June 2024
,
Page 143-152
https://doi.org/10.22037/ijps.v20i2.44546
Abstract
The scientific authority refers to social power of scientific knowledge, in different sciences. The aim of this study is to present the role of Iranian pharmaceutical research centers in scientific authority based on research evaluation for a decade. Iranian pharmaceutical research centers with more than one year of activity from 2013 to 2022 were assessed based on the intervention model of evaluation system. Three domains including stewardship, knowledge production and research impact with 20 indicators have been used in this process. 36 pharmaceutical sciences research centers (PhRCs) related to 23 universities of Medical Sciences (UMSs) were evaluated for a decade. The mean and standard deviation (SD) of age of the research activities in PhRCs was 12.2 ± 8.60. The ratio of faculty member to research center was 10.5. The total number of published articles was 20166 and 70% of which were indexed in ISI –WOS.34.2% and 21.7% of them were published in the first quantile journals and with international collaboration respectively. Based on research ranking, the first three centers were Tabriz Applied Pharmaceutical Science Research Center, Mashhad Pharmaceutical Sciences Research Center and Tabriz Pharmaceutical Nanotechnology research center. Mission oriented research activities in Iranian pharmaceutical research centers may lead them in achieving scientific authority.
- Scientific authority
- Pharmacy
- Research center
- Evaluation
- Healthcare research
How to Cite
References
Gauchat G. The cultural authority of science: Public trust and acceptance of organized science. Public Underst Sci (2011) 20 (6): 751-770.
Cahlíková L, Šafratová M, Hošťálková A, Chlebek J, Hulcová D, Breiterová K, Opletal L. Pharmacognosy and its role in the system of profile disciplines in pharmacy. Nat Prod Commun (2020) 15 (9):1934578X20945450.
Ahmad I, Aqil F, Ahmad F. Owais M. Modern phytomedicine: turning medicinal plants into drugs., Wiley‐VCH Verlag GmbH & Co. KGaA (2006).
Boivin R. Risks, prices, and positions: A social network analysis of illegal drug trafficking in the world-economy. Int J Drug Policy (2014) 25(2): 235-243.
Bond CA, Raehl CL, Franke T. Clinical pharmacy services, pharmacy staffing, and the total cost of care in United States hospitals. Pharmacotherapy (2000) 20(6):609-621.
David B, Wolfender JL, Dias DA. The pharmaceutical industry and natural products: historical status and new trends. Phytochemistry Rev (2015) 14:299-315.
DeVries R, Lemmens T. The social and cultural shaping of medical evidence: case studies from pharmaceutical research and obstetric science. Soc Sci Med (2006) 62(11): 2694-706.
Du J, Li P, Guo Q, Tang X. Measuring the knowledge translation and convergence in pharmaceutical innovation by funding-science-technology-innovation linkages analysis. J informetr (2019) 13(1):132-148.
Kumar V. The role of university research centers in promoting research. J Acad Mark Sci ( 2017) l(45): 453-8.
Tash WR. Evaluating research centers and institutes for success., Bill Tash: Philadelphia (2006).
The list of approved Medical Rrsearch Centers. Deputy for Research and Technology, Ministry of Health and Medical Education. https://www. research.behdasht.gov.ir/ru (Accessed Nov 6, 2023).
Shapiro ES, Clemens NH. A conceptual model for evaluating system effects of response to intervention. Assess Eff Interv (2009) 35(1):3-16.
Peykari N, Djalalinia S, Owlia P, Habibi E, Falahat K, Ghanei M. Health research system evaluation in IR of Iran. Arch Iran Med (2012) 15(7).
Gaffey V. A fresh look at the intervention logic of Structural Funds. Evaluation (2013) 19(2): 195-203.
Mazzucato M. Mission-oriented innovation policies: challenges and opportunities. Indust Corp Change (2018) 27 (5): 803-815.
Adam P. ISRIA statement: ten-point guidelines for an effective process of research impact assessment. Hlth Res Policy Syst ( 2018) 16: 1-16.
Bond C. Pharmacy Practice Research: Evidence, Impact and Synthesis. Pharm pract res methods (2020) 1-30.
Sosa DN, Altman RB. Contexts and contradictions: a roadmap for computational drug repurposing with knowledge inference. Brief Bioinform (2022) 23(4): 268.
Omran MA, Al Mousawi HA. The Projects of Pharmaceutical Industry in Iraq for the Period (2014-2021): Developments and Challenges. Mathematical Statistician and Engineering Applications (2022) 1(4):4208-4229.
Messemeche N, Berkane D, Hani N. The reality of the Pharmaceutical Industry and the Challenges it faces Globally. Dirassat J Economic Issue (2021) 12 (1): 461-479.
Jamshidi-Kia F, Lorigooini Z, Amini-Khoei H. Medicinal plants: Past history and future perspective. J herbmed pharm (2017) 7(1): 1-7.
- Abstract Viewed: 192 times
- IJPS_Volume20_Issue2_Pages 143-152 Downloaded: 125 times